CM-TMA Biomarker Detection via Complement Factor Ba and sC5b9 Signatures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective detection of complement-mediated thrombotic microangiopathy (CM-TMA) biomarkers for diagnosis, as existing methods are inadequate for accurately diagnosing and managing CM-TMA, particularly in cases resistant to conventional treatments.
Innovation Solution
The use of specific protein biomarkers such as cystatin C, complement factor Ba, and soluble C5b-9, along with their ratios with creatinine, to create a biomarker signature that includes at least two biomarkers like Ba and sC5b9 for diagnosing CM-TMA and monitoring responsiveness to anti-C5 antibody therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for CM-TMA, then the diagnosis process is simple, but the accuracy and reliability of diagnosis is insufficient
Solution Approach 1:
The diagnostic approach segments the detection task by identifying and measuring specific biomarkers (complement factor Ba, sC5b9, cystatin C) separately from the complex disease process. Each biomarker serves as an independent detection target, allowing precise measurement of complement activation status without requiring complex overall system analysis.
Solution Approach 2:
The patent uses biomarkers as intermediary substances that mediate between the complex pathophysiological processes of CM-TMA and the detection system. These biomarkers (Ba, sC5b9, cystatin C) serve as measurable proxies that reflect complement activation and kidney injury without requiring direct observation of the complex disease mechanisms.
2Reliability
If multiple biomarkers are detected to improve diagnosis accuracy, then the diagnostic reliability improves, but the complexity of the detection process increases
Solution Approach 1:
The patent merges multiple biomarkers (complement factor Ba, sC5b9, and cystatin C) into a comprehensive detection panel that works synergistically to diagnose CM-TMA. By combining these markers, the system achieves higher diagnostic reliability than any single marker could provide alone, as they collectively capture different aspects of the disease pathology.
Solution Approach 2:
The biomarker panel serves multiple functions simultaneously: it diagnoses CM-TMA, monitors treatment response to anti-C5 antibodies, and predicts disease progression. This multi-functionality allows a single detection system to handle various clinical needs without requiring separate specialized assays for each purpose.
3Reliability
If baseline biomarker levels are measured to monitor treatment response, then the monitoring of therapy effectiveness improves, but the frequency and burden of testing increases
Solution Approach 1:
The patent implements a feedback mechanism where baseline biomarker levels are measured before treatment initiation, and subsequent measurements are compared to the baseline to assess treatment response. This feedback loop provides reliable monitoring of therapy effectiveness by quantifying changes in biomarker levels over time, allowing clinicians to adjust treatment based on objective data.
Solution Approach 2:
The monitoring approach relies on detecting parameter changes in biomarker levels rather than requiring frequent complex assessments. By tracking changes in biomarker concentrations (such as reductions in Ba and sC5b9 levels), the system can reliably monitor treatment response with reasonable testing frequency, as biomarker changes provide sensitive indicators of therapeutic effect.
Data Source
AI summary
Provided are agents and methods for the detection of complement-mediated thrombotic microangiopathy (CM-TMA) biomarkers. The agents may specifically bind to CM-TMA biomarkers, preferably a proteolytic fragment of complement component factor B (Ba) and soluble C5b9 (sC5b9) and can be used in methods of diagnosis and treatment of CM-TMA, e.g., treatment with an anti-C5 antibody such as ravulizumab (ALXN1210).